Engineering a single-agent cytokine-antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy.

Interleukin-2 (IL-2) has been used to treat diseases ranging from cancer to autoimmune disorders, but its concurrent immunostimulatory and immunosuppressive effects hinder efficacy. IL-2 orchestrates immune cell function through activation of a high-affinity heterotrimeric receptor (comprised of IL-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunol
Principais autores: Spangler, Jamie B., Trotta, Eleonora, Tomala, Jakub, Peck, Ariana, Young, Tracy A., Savvides, Christina S., Silveria, Stephanie, Votavova, Petra, Salafsky, Joshua, Pande, Vijay S., Kovar, Marek, Bluestone, Jeffrey A., Garcia, K. Christopher
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6173196/
https://ncbi.nlm.nih.gov/pubmed/30104245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1800578
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados